DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cilostazol (Cilostazol) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.

DOSAGE AND ADMINISTRATION

The recommended dosage of cilostazol tablets USP is 100 mg b.i.d. taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg b.i.d. should be considered during coadministration of such inhibitors of CYP3A4 as ketoconazole, itraconazole, erythromycin and diltiazem, and during coadministration of such inhibitors of CYP2C19 as omeprazole.

Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.

Discontinuation of Therapy

The available data suggest that the dosage of cilostazol tablets, USP can be reduced or discontinued without rebound (i.e., platelet hyperaggregability).

HOW SUPPLIED

Cilostazol tablets are available as follows:

50 mg - white to off-white, pillow-shaped tablets, debossed with “TEVA” on one side and “7230” on the other.

100 mg - white to off-white, round tablets, debossed with “TEVA” on one side and “7231” on the other, available in blisterpacks of 30.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured In India By:

PIRAMAL HEALTHCARE LIMITED

Pithampur, Madhya Pradesh, India

Manufactured For:

TEVA PHARMACEUTICALS USA

Sellersville, PA 18960

Rev. J 2/2012

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017